No­var­tis ties a new round of biosim­i­lar de­vel­op­ment pro­grams to a part­ner­ship deal with In­di­a's Bio­con

Just a few weeks af­ter Bio­con and their part­ners at My­lan worked out an FDA ap­proval for the first Her­ceptin biosim­i­lar, the In­di­an com­pa­ny has struck a wide rang­ing de­vel­op­ment deal with No­var­tis’ gener­ics arm.

Bio­con and San­doz — which has al­ready de­vel­oped a slate of 5 bi­o­log­ic knock­offs — will go to work on im­munol­o­gy and on­col­o­gy pro­grams to­geth­er. They plan to share de­vel­op­ment, man­u­fac­tur­ing and reg­u­la­to­ry costs while split­ting the prof­its on “a num­ber” of new ther­a­pies.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.